nodes	percent_of_prediction	percent_of_DWPC	metapath
Sorafenib—ABCG2—Cladribine—multiple sclerosis	0.0495	0.11	CbGbCtD
Sorafenib—ABCG2—Mitoxantrone—multiple sclerosis	0.0361	0.08	CbGbCtD
Sorafenib—ABCC4—Methotrexate—multiple sclerosis	0.028	0.062	CbGbCtD
Sorafenib—CYP2D6—Fingolimod—multiple sclerosis	0.0261	0.0578	CbGbCtD
Sorafenib—ABCC2—Dexamethasone—multiple sclerosis	0.0207	0.0459	CbGbCtD
Sorafenib—ABCG2—Dexamethasone—multiple sclerosis	0.0187	0.0415	CbGbCtD
Sorafenib—ABCB1—Methylprednisolone—multiple sclerosis	0.0179	0.0395	CbGbCtD
Sorafenib—ABCC2—Methotrexate—multiple sclerosis	0.0167	0.0369	CbGbCtD
Sorafenib—CYP3A4—Fingolimod—multiple sclerosis	0.0166	0.0368	CbGbCtD
Sorafenib—ABCG2—Methotrexate—multiple sclerosis	0.0151	0.0333	CbGbCtD
Sorafenib—CYP3A7—Dexamethasone—multiple sclerosis	0.0138	0.0306	CbGbCtD
Sorafenib—CYP3A7-CYP3A51P—Dexamethasone—multiple sclerosis	0.0138	0.0306	CbGbCtD
Sorafenib—CYP2C19—Prednisone—multiple sclerosis	0.0134	0.0297	CbGbCtD
Sorafenib—CYP2B6—Dexamethasone—multiple sclerosis	0.0132	0.0292	CbGbCtD
Sorafenib—ABCB1—Mitoxantrone—multiple sclerosis	0.013	0.0288	CbGbCtD
Sorafenib—ABCB1—Betamethasone—multiple sclerosis	0.0116	0.0257	CbGbCtD
Sorafenib—ABCB1—Prednisolone—multiple sclerosis	0.0115	0.0254	CbGbCtD
Sorafenib—ABCB1—Prednisone—multiple sclerosis	0.0108	0.0239	CbGbCtD
Sorafenib—CYP3A4—Methylprednisolone—multiple sclerosis	0.0107	0.0237	CbGbCtD
Sorafenib—CYP3A5—Dexamethasone—multiple sclerosis	0.0104	0.023	CbGbCtD
Sorafenib—CYP2C8—Dexamethasone—multiple sclerosis	0.00998	0.0221	CbGbCtD
Sorafenib—CYP2C19—Dexamethasone—multiple sclerosis	0.00837	0.0185	CbGbCtD
Sorafenib—CYP3A4—Triamcinolone—multiple sclerosis	0.00811	0.0179	CbGbCtD
Sorafenib—CYP3A4—Mitoxantrone—multiple sclerosis	0.00781	0.0173	CbGbCtD
Sorafenib—CYP2C9—Dexamethasone—multiple sclerosis	0.00696	0.0154	CbGbCtD
Sorafenib—CYP3A4—Betamethasone—multiple sclerosis	0.00696	0.0154	CbGbCtD
Sorafenib—CYP3A4—Prednisolone—multiple sclerosis	0.00686	0.0152	CbGbCtD
Sorafenib—ABCB1—Dexamethasone—multiple sclerosis	0.00675	0.015	CbGbCtD
Sorafenib—CYP3A4—Prednisone—multiple sclerosis	0.00648	0.0143	CbGbCtD
Sorafenib—CYP2D6—Dexamethasone—multiple sclerosis	0.00636	0.0141	CbGbCtD
Sorafenib—ABCB1—Methotrexate—multiple sclerosis	0.00543	0.012	CbGbCtD
Sorafenib—CYP3A4—Dexamethasone—multiple sclerosis	0.00405	0.00896	CbGbCtD
Sorafenib—MAPK15—brainstem—multiple sclerosis	0.00338	0.0267	CbGeAlD
Sorafenib—MUSK—nervous system—multiple sclerosis	0.00241	0.0191	CbGeAlD
Sorafenib—MAPK15—medulla oblongata—multiple sclerosis	0.00235	0.0186	CbGeAlD
Sorafenib—CDKL2—nervous system—multiple sclerosis	0.00196	0.0155	CbGeAlD
Sorafenib—CDKL2—central nervous system—multiple sclerosis	0.00189	0.015	CbGeAlD
Sorafenib—MAPK15—nervous system—multiple sclerosis	0.00177	0.014	CbGeAlD
Sorafenib—MAPK15—central nervous system—multiple sclerosis	0.0017	0.0135	CbGeAlD
Sorafenib—CDKL3—brain—multiple sclerosis	0.00164	0.013	CbGeAlD
Sorafenib—HIPK3—retina—multiple sclerosis	0.00161	0.0127	CbGeAlD
Sorafenib—CDKL2—brain—multiple sclerosis	0.0015	0.0119	CbGeAlD
Sorafenib—EPHX2—retina—multiple sclerosis	0.00138	0.0109	CbGeAlD
Sorafenib—MAPK15—brain—multiple sclerosis	0.00135	0.0107	CbGeAlD
Sorafenib—MAP3K7—retina—multiple sclerosis	0.00116	0.00918	CbGeAlD
Sorafenib—MKNK2—retina—multiple sclerosis	0.00112	0.00889	CbGeAlD
Sorafenib—MKNK1—retina—multiple sclerosis	0.00111	0.00878	CbGeAlD
Sorafenib—MAPK11—nervous system—multiple sclerosis	0.00105	0.0083	CbGeAlD
Sorafenib—CDK7—nervous system—multiple sclerosis	0.00103	0.00817	CbGeAlD
Sorafenib—AURKC—nervous system—multiple sclerosis	0.00102	0.00804	CbGeAlD
Sorafenib—RALBP1—retina—multiple sclerosis	0.00101	0.00803	CbGeAlD
Sorafenib—MAPK11—central nervous system—multiple sclerosis	0.00101	0.00799	CbGeAlD
Sorafenib—RAF1—brainstem—multiple sclerosis	0.000994	0.00787	CbGeAlD
Sorafenib—CDK7—central nervous system—multiple sclerosis	0.000993	0.00786	CbGeAlD
Sorafenib—MAPK11—cerebellum—multiple sclerosis	0.000987	0.00781	CbGeAlD
Sorafenib—AURKC—central nervous system—multiple sclerosis	0.000978	0.00774	CbGeAlD
Sorafenib—CDK7—cerebellum—multiple sclerosis	0.000971	0.00769	CbGeAlD
Sorafenib—FLT1—retina—multiple sclerosis	0.000965	0.00764	CbGeAlD
Sorafenib—TAOK2—cerebellum—multiple sclerosis	0.000963	0.00763	CbGeAlD
Sorafenib—BRAF—midbrain—multiple sclerosis	0.000951	0.00753	CbGeAlD
Sorafenib—EPHA6—nervous system—multiple sclerosis	0.000941	0.00745	CbGeAlD
Sorafenib—HIPK4—brain—multiple sclerosis	0.00091	0.0072	CbGeAlD
Sorafenib—EPHA6—central nervous system—multiple sclerosis	0.000906	0.00717	CbGeAlD
Sorafenib—ZAK—nervous system—multiple sclerosis	0.000892	0.00706	CbGeAlD
Sorafenib—FGFR1—medulla oblongata—multiple sclerosis	0.000885	0.00701	CbGeAlD
Sorafenib—ZAK—central nervous system—multiple sclerosis	0.000859	0.0068	CbGeAlD
Sorafenib—MAP3K19—nervous system—multiple sclerosis	0.000855	0.00677	CbGeAlD
Sorafenib—MAP2K5—brainstem—multiple sclerosis	0.000845	0.00669	CbGeAlD
Sorafenib—ZAK—cerebellum—multiple sclerosis	0.000839	0.00664	CbGeAlD
Sorafenib—MAP3K7—medulla oblongata—multiple sclerosis	0.000838	0.00663	CbGeAlD
Sorafenib—MAP3K19—central nervous system—multiple sclerosis	0.000823	0.00652	CbGeAlD
Sorafenib—HIPK3—cerebellum—multiple sclerosis	0.000821	0.0065	CbGeAlD
Sorafenib—KDR—retina—multiple sclerosis	0.000816	0.00646	CbGeAlD
Sorafenib—TIE1—nervous system—multiple sclerosis	0.000816	0.00646	CbGeAlD
Sorafenib—MKNK2—medulla oblongata—multiple sclerosis	0.000812	0.00643	CbGeAlD
Sorafenib—FGFR1—midbrain—multiple sclerosis	0.000809	0.0064	CbGeAlD
Sorafenib—MKNK1—medulla oblongata—multiple sclerosis	0.000802	0.00635	CbGeAlD
Sorafenib—MAPK11—brain—multiple sclerosis	0.000802	0.00635	CbGeAlD
Sorafenib—RET—medulla oblongata—multiple sclerosis	0.000792	0.00627	CbGeAlD
Sorafenib—FGFR1—spinal cord—multiple sclerosis	0.000789	0.00625	CbGeAlD
Sorafenib—CDK7—brain—multiple sclerosis	0.000789	0.00624	CbGeAlD
Sorafenib—TIE1—central nervous system—multiple sclerosis	0.000785	0.00622	CbGeAlD
Sorafenib—TAOK2—brain—multiple sclerosis	0.000782	0.00619	CbGeAlD
Sorafenib—AURKC—brain—multiple sclerosis	0.000776	0.00615	CbGeAlD
Sorafenib—TIE1—cerebellum—multiple sclerosis	0.000767	0.00608	CbGeAlD
Sorafenib—MAP3K7—midbrain—multiple sclerosis	0.000766	0.00606	CbGeAlD
Sorafenib—KIT—brainstem—multiple sclerosis	0.000749	0.00593	CbGeAlD
Sorafenib—MAP3K7—spinal cord—multiple sclerosis	0.000747	0.00591	CbGeAlD
Sorafenib—MKNK2—midbrain—multiple sclerosis	0.000742	0.00587	CbGeAlD
Sorafenib—BRAF—cerebellum—multiple sclerosis	0.000736	0.00583	CbGeAlD
Sorafenib—RALBP1—medulla oblongata—multiple sclerosis	0.000733	0.0058	CbGeAlD
Sorafenib—MKNK1—midbrain—multiple sclerosis	0.000733	0.0058	CbGeAlD
Sorafenib—MKNK2—spinal cord—multiple sclerosis	0.000724	0.00573	CbGeAlD
Sorafenib—RET—midbrain—multiple sclerosis	0.000724	0.00573	CbGeAlD
Sorafenib—EPHA6—brain—multiple sclerosis	0.000719	0.00569	CbGeAlD
Sorafenib—MKNK1—spinal cord—multiple sclerosis	0.000715	0.00566	CbGeAlD
Sorafenib—RET—spinal cord—multiple sclerosis	0.000706	0.00559	CbGeAlD
Sorafenib—EPHX2—cerebellum—multiple sclerosis	0.000703	0.00557	CbGeAlD
Sorafenib—FLT3—cerebellum—multiple sclerosis	0.000698	0.00553	CbGeAlD
Sorafenib—FLT1—medulla oblongata—multiple sclerosis	0.000697	0.00552	CbGeAlD
Sorafenib—RAF1—medulla oblongata—multiple sclerosis	0.000693	0.00549	CbGeAlD
Sorafenib—EPHB6—medulla oblongata—multiple sclerosis	0.000689	0.00546	CbGeAlD
Sorafenib—ZAK—brain—multiple sclerosis	0.000682	0.0054	CbGeAlD
Sorafenib—RALBP1—midbrain—multiple sclerosis	0.00067	0.00531	CbGeAlD
Sorafenib—HIPK3—brain—multiple sclerosis	0.000667	0.00528	CbGeAlD
Sorafenib—RALBP1—spinal cord—multiple sclerosis	0.000654	0.00518	CbGeAlD
Sorafenib—MAP3K19—brain—multiple sclerosis	0.000653	0.00517	CbGeAlD
Sorafenib—FLT1—midbrain—multiple sclerosis	0.000637	0.00505	CbGeAlD
Sorafenib—RAF1—midbrain—multiple sclerosis	0.000634	0.00502	CbGeAlD
Sorafenib—EPHB6—midbrain—multiple sclerosis	0.00063	0.00499	CbGeAlD
Sorafenib—FGFR1—cerebellum—multiple sclerosis	0.000626	0.00495	CbGeAlD
Sorafenib—TIE1—brain—multiple sclerosis	0.000623	0.00494	CbGeAlD
Sorafenib—FLT1—spinal cord—multiple sclerosis	0.000622	0.00492	CbGeAlD
Sorafenib—RAF1—spinal cord—multiple sclerosis	0.000618	0.00489	CbGeAlD
Sorafenib—HTR2C—brainstem—multiple sclerosis	0.000617	0.00488	CbGeAlD
Sorafenib—EPHB6—spinal cord—multiple sclerosis	0.000615	0.00487	CbGeAlD
Sorafenib—MKNK2—nervous system—multiple sclerosis	0.00061	0.00483	CbGeAlD
Sorafenib—MKNK1—nervous system—multiple sclerosis	0.000602	0.00477	CbGeAlD
Sorafenib—BRAF—brain—multiple sclerosis	0.000598	0.00473	CbGeAlD
Sorafenib—RET—nervous system—multiple sclerosis	0.000595	0.00471	CbGeAlD
Sorafenib—MAP3K7—cerebellum—multiple sclerosis	0.000592	0.00469	CbGeAlD
Sorafenib—KDR—medulla oblongata—multiple sclerosis	0.00059	0.00467	CbGeAlD
Sorafenib—MAP2K5—medulla oblongata—multiple sclerosis	0.00059	0.00467	CbGeAlD
Sorafenib—MKNK2—central nervous system—multiple sclerosis	0.000587	0.00465	CbGeAlD
Sorafenib—PDGFRA—spinal cord—multiple sclerosis	0.000583	0.00461	CbGeAlD
Sorafenib—MKNK1—central nervous system—multiple sclerosis	0.00058	0.00459	CbGeAlD
Sorafenib—CSF1R—medulla oblongata—multiple sclerosis	0.000575	0.00455	CbGeAlD
Sorafenib—MKNK2—cerebellum—multiple sclerosis	0.000574	0.00454	CbGeAlD
Sorafenib—RET—central nervous system—multiple sclerosis	0.000573	0.00453	CbGeAlD
Sorafenib—EPHX2—brain—multiple sclerosis	0.000571	0.00452	CbGeAlD
Sorafenib—MKNK1—cerebellum—multiple sclerosis	0.000567	0.00449	CbGeAlD
Sorafenib—RET—cerebellum—multiple sclerosis	0.00056	0.00443	CbGeAlD
Sorafenib—RALBP1—nervous system—multiple sclerosis	0.000551	0.00436	CbGeAlD
Sorafenib—MAP2K5—midbrain—multiple sclerosis	0.000539	0.00427	CbGeAlD
Sorafenib—KDR—midbrain—multiple sclerosis	0.000539	0.00427	CbGeAlD
Sorafenib—RALBP1—central nervous system—multiple sclerosis	0.00053	0.0042	CbGeAlD
Sorafenib—CSF1R—midbrain—multiple sclerosis	0.000526	0.00416	CbGeAlD
Sorafenib—KDR—spinal cord—multiple sclerosis	0.000526	0.00416	CbGeAlD
Sorafenib—MAP2K5—spinal cord—multiple sclerosis	0.000526	0.00416	CbGeAlD
Sorafenib—FLT1—nervous system—multiple sclerosis	0.000524	0.00415	CbGeAlD
Sorafenib—KIT—medulla oblongata—multiple sclerosis	0.000522	0.00414	CbGeAlD
Sorafenib—RAF1—nervous system—multiple sclerosis	0.000521	0.00412	CbGeAlD
Sorafenib—RALBP1—cerebellum—multiple sclerosis	0.000518	0.0041	CbGeAlD
Sorafenib—EPHB6—nervous system—multiple sclerosis	0.000518	0.0041	CbGeAlD
Sorafenib—FLT4—brain—multiple sclerosis	0.000515	0.00408	CbGeAlD
Sorafenib—CSF1R—spinal cord—multiple sclerosis	0.000513	0.00406	CbGeAlD
Sorafenib—PDGFRB—medulla oblongata—multiple sclerosis	0.00051	0.00404	CbGeAlD
Sorafenib—FGFR1—brain—multiple sclerosis	0.000508	0.00402	CbGeAlD
Sorafenib—FLT1—central nervous system—multiple sclerosis	0.000505	0.00399	CbGeAlD
Sorafenib—RAF1—central nervous system—multiple sclerosis	0.000502	0.00397	CbGeAlD
Sorafenib—EPHB6—central nervous system—multiple sclerosis	0.000499	0.00395	CbGeAlD
Sorafenib—STK10—nervous system—multiple sclerosis	0.000496	0.00393	CbGeAlD
Sorafenib—FLT1—cerebellum—multiple sclerosis	0.000493	0.0039	CbGeAlD
Sorafenib—PDGFRA—nervous system—multiple sclerosis	0.000491	0.00389	CbGeAlD
Sorafenib—RAF1—cerebellum—multiple sclerosis	0.00049	0.00388	CbGeAlD
Sorafenib—EPHB6—cerebellum—multiple sclerosis	0.000487	0.00386	CbGeAlD
Sorafenib—MAP3K7—brain—multiple sclerosis	0.000481	0.00381	CbGeAlD
Sorafenib—STK10—central nervous system—multiple sclerosis	0.000478	0.00378	CbGeAlD
Sorafenib—KIT—midbrain—multiple sclerosis	0.000477	0.00378	CbGeAlD
Sorafenib—PDGFRA—central nervous system—multiple sclerosis	0.000473	0.00374	CbGeAlD
Sorafenib—STK10—cerebellum—multiple sclerosis	0.000467	0.0037	CbGeAlD
Sorafenib—PDGFRB—midbrain—multiple sclerosis	0.000466	0.00369	CbGeAlD
Sorafenib—MKNK2—brain—multiple sclerosis	0.000466	0.00369	CbGeAlD
Sorafenib—KIT—spinal cord—multiple sclerosis	0.000466	0.00369	CbGeAlD
Sorafenib—PDGFRA—cerebellum—multiple sclerosis	0.000462	0.00366	CbGeAlD
Sorafenib—MKNK1—brain—multiple sclerosis	0.00046	0.00364	CbGeAlD
Sorafenib—PDGFRB—spinal cord—multiple sclerosis	0.000455	0.0036	CbGeAlD
Sorafenib—RET—brain—multiple sclerosis	0.000455	0.0036	CbGeAlD
Sorafenib—MAP2K5—nervous system—multiple sclerosis	0.000443	0.00351	CbGeAlD
Sorafenib—KDR—nervous system—multiple sclerosis	0.000443	0.00351	CbGeAlD
Sorafenib—CSF1R—nervous system—multiple sclerosis	0.000432	0.00342	CbGeAlD
Sorafenib—HTR2C—medulla oblongata—multiple sclerosis	0.00043	0.00341	CbGeAlD
Sorafenib—MAP2K5—central nervous system—multiple sclerosis	0.000426	0.00338	CbGeAlD
Sorafenib—KDR—central nervous system—multiple sclerosis	0.000426	0.00338	CbGeAlD
Sorafenib—RALBP1—brain—multiple sclerosis	0.000421	0.00333	CbGeAlD
Sorafenib—MAP2K5—cerebellum—multiple sclerosis	0.000417	0.0033	CbGeAlD
Sorafenib—KDR—cerebellum—multiple sclerosis	0.000417	0.0033	CbGeAlD
Sorafenib—CSF1R—central nervous system—multiple sclerosis	0.000416	0.00329	CbGeAlD
Sorafenib—CSF1R—cerebellum—multiple sclerosis	0.000407	0.00322	CbGeAlD
Sorafenib—FLT1—brain—multiple sclerosis	0.000401	0.00317	CbGeAlD
Sorafenib—RAF1—brain—multiple sclerosis	0.000398	0.00315	CbGeAlD
Sorafenib—EPHB6—brain—multiple sclerosis	0.000396	0.00313	CbGeAlD
Sorafenib—HTR2C—midbrain—multiple sclerosis	0.000393	0.00311	CbGeAlD
Sorafenib—KIT—nervous system—multiple sclerosis	0.000393	0.00311	CbGeAlD
Sorafenib—HTR2C—spinal cord—multiple sclerosis	0.000384	0.00304	CbGeAlD
Sorafenib—PDGFRB—nervous system—multiple sclerosis	0.000383	0.00304	CbGeAlD
Sorafenib—STK10—brain—multiple sclerosis	0.000379	0.003	CbGeAlD
Sorafenib—KIT—central nervous system—multiple sclerosis	0.000378	0.00299	CbGeAlD
Sorafenib—PDGFRA—brain—multiple sclerosis	0.000375	0.00297	CbGeAlD
Sorafenib—KIT—cerebellum—multiple sclerosis	0.000369	0.00292	CbGeAlD
Sorafenib—PDGFRB—central nervous system—multiple sclerosis	0.000369	0.00292	CbGeAlD
Sorafenib—PDGFRB—cerebellum—multiple sclerosis	0.000361	0.00286	CbGeAlD
Sorafenib—MAP2K5—brain—multiple sclerosis	0.000339	0.00268	CbGeAlD
Sorafenib—KDR—brain—multiple sclerosis	0.000339	0.00268	CbGeAlD
Sorafenib—CSF1R—brain—multiple sclerosis	0.00033	0.00262	CbGeAlD
Sorafenib—HTR2C—nervous system—multiple sclerosis	0.000323	0.00256	CbGeAlD
Sorafenib—HTR2C—central nervous system—multiple sclerosis	0.000311	0.00246	CbGeAlD
Sorafenib—ABCC4—nervous system—multiple sclerosis	0.000305	0.00242	CbGeAlD
Sorafenib—HTR2B—nervous system—multiple sclerosis	0.000304	0.0024	CbGeAlD
Sorafenib—KIT—brain—multiple sclerosis	0.0003	0.00238	CbGeAlD
Sorafenib—ABCC4—central nervous system—multiple sclerosis	0.000294	0.00233	CbGeAlD
Sorafenib—PDGFRB—brain—multiple sclerosis	0.000293	0.00232	CbGeAlD
Sorafenib—HTR2B—central nervous system—multiple sclerosis	0.000292	0.00231	CbGeAlD
Sorafenib—ABCG2—medulla oblongata—multiple sclerosis	0.000287	0.00227	CbGeAlD
Sorafenib—CYP2D6—brainstem—multiple sclerosis	0.000282	0.00223	CbGeAlD
Sorafenib—ABCG2—midbrain—multiple sclerosis	0.000262	0.00208	CbGeAlD
Sorafenib—ABCG2—spinal cord—multiple sclerosis	0.000256	0.00202	CbGeAlD
Sorafenib—HTR2C—brain—multiple sclerosis	0.000247	0.00196	CbGeAlD
Sorafenib—ABCC4—brain—multiple sclerosis	0.000233	0.00185	CbGeAlD
Sorafenib—HTR2B—brain—multiple sclerosis	0.000232	0.00184	CbGeAlD
Sorafenib—ABCG2—cerebellum—multiple sclerosis	0.000203	0.00161	CbGeAlD
Sorafenib—CYP2B6—nervous system—multiple sclerosis	0.000199	0.00157	CbGeAlD
Sorafenib—ABCB1—retina—multiple sclerosis	0.000196	0.00155	CbGeAlD
Sorafenib—CYP2B6—central nervous system—multiple sclerosis	0.000191	0.00152	CbGeAlD
Sorafenib—Alopecia—Betamethasone—multiple sclerosis	0.000175	0.00088	CcSEcCtD
Sorafenib—Alopecia—Dexamethasone—multiple sclerosis	0.000175	0.00088	CcSEcCtD
Sorafenib—Diarrhoea—Azathioprine—multiple sclerosis	0.000174	0.000874	CcSEcCtD
Sorafenib—Angioedema—Triamcinolone—multiple sclerosis	0.000173	0.000873	CcSEcCtD
Sorafenib—Haemoglobin—Prednisone—multiple sclerosis	0.000173	0.000871	CcSEcCtD
Sorafenib—Angioedema—Methylprednisolone—multiple sclerosis	0.000173	0.000871	CcSEcCtD
Sorafenib—Abdominal discomfort—Methotrexate—multiple sclerosis	0.000172	0.000868	CcSEcCtD
Sorafenib—Haemorrhage—Prednisone—multiple sclerosis	0.000172	0.000867	CcSEcCtD
Sorafenib—Erythema—Dexamethasone—multiple sclerosis	0.000172	0.000866	CcSEcCtD
Sorafenib—Erythema—Betamethasone—multiple sclerosis	0.000172	0.000866	CcSEcCtD
Sorafenib—Syncope—Triamcinolone—multiple sclerosis	0.00017	0.000856	CcSEcCtD
Sorafenib—Syncope—Methylprednisolone—multiple sclerosis	0.00017	0.000854	CcSEcCtD
Sorafenib—CYP2C8—brain—multiple sclerosis	0.000169	0.00134	CbGeAlD
Sorafenib—Connective tissue disorder—Prednisone—multiple sclerosis	0.000169	0.000852	CcSEcCtD
Sorafenib—Anaphylactic shock—Prednisolone—multiple sclerosis	0.000168	0.000847	CcSEcCtD
Sorafenib—Neutropenia—Methotrexate—multiple sclerosis	0.000168	0.000846	CcSEcCtD
Sorafenib—Dizziness—Azathioprine—multiple sclerosis	0.000168	0.000845	CcSEcCtD
Sorafenib—Gastrointestinal pain—Mitoxantrone—multiple sclerosis	0.000168	0.000845	CcSEcCtD
Sorafenib—Loss of consciousness—Triamcinolone—multiple sclerosis	0.000167	0.000839	CcSEcCtD
Sorafenib—Loss of consciousness—Methylprednisolone—multiple sclerosis	0.000166	0.000837	CcSEcCtD
Sorafenib—Shock—Prednisolone—multiple sclerosis	0.000166	0.000834	CcSEcCtD
Sorafenib—Erectile dysfunction—Methotrexate—multiple sclerosis	0.000166	0.000834	CcSEcCtD
Sorafenib—Cough—Triamcinolone—multiple sclerosis	0.000165	0.000833	CcSEcCtD
Sorafenib—ABCG2—brain—multiple sclerosis	0.000165	0.0013	CbGeAlD
Sorafenib—Hypertension—Triamcinolone—multiple sclerosis	0.000164	0.000824	CcSEcCtD
Sorafenib—Hypertension—Methylprednisolone—multiple sclerosis	0.000163	0.000823	CcSEcCtD
Sorafenib—Urticaria—Mitoxantrone—multiple sclerosis	0.000163	0.000821	CcSEcCtD
Sorafenib—Body temperature increased—Mitoxantrone—multiple sclerosis	0.000162	0.000817	CcSEcCtD
Sorafenib—Abdominal pain—Mitoxantrone—multiple sclerosis	0.000162	0.000817	CcSEcCtD
Sorafenib—Myalgia—Triamcinolone—multiple sclerosis	0.000161	0.000813	CcSEcCtD
Sorafenib—Vomiting—Azathioprine—multiple sclerosis	0.000161	0.000812	CcSEcCtD
Sorafenib—Pneumonia—Methotrexate—multiple sclerosis	0.000161	0.000812	CcSEcCtD
Sorafenib—Myalgia—Methylprednisolone—multiple sclerosis	0.000161	0.000811	CcSEcCtD
Sorafenib—Arthralgia—Methylprednisolone—multiple sclerosis	0.000161	0.000811	CcSEcCtD
Sorafenib—Infestation—Methotrexate—multiple sclerosis	0.00016	0.000807	CcSEcCtD
Sorafenib—Infestation NOS—Methotrexate—multiple sclerosis	0.00016	0.000807	CcSEcCtD
Sorafenib—Rash—Azathioprine—multiple sclerosis	0.00016	0.000806	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	0.00016	0.000806	CcSEcCtD
Sorafenib—Dermatitis—Azathioprine—multiple sclerosis	0.00016	0.000805	CcSEcCtD
Sorafenib—Flushing—Prednisone—multiple sclerosis	0.00016	0.000804	CcSEcCtD
Sorafenib—Headache—Azathioprine—multiple sclerosis	0.000159	0.000801	CcSEcCtD
Sorafenib—Stevens-Johnson syndrome—Methotrexate—multiple sclerosis	0.000159	0.0008	CcSEcCtD
Sorafenib—Dry mouth—Triamcinolone—multiple sclerosis	0.000158	0.000795	CcSEcCtD
Sorafenib—Renal failure—Methotrexate—multiple sclerosis	0.000158	0.000793	CcSEcCtD
Sorafenib—Angioedema—Dexamethasone—multiple sclerosis	0.000157	0.000792	CcSEcCtD
Sorafenib—Angioedema—Betamethasone—multiple sclerosis	0.000157	0.000792	CcSEcCtD
Sorafenib—Stomatitis—Methotrexate—multiple sclerosis	0.000156	0.000787	CcSEcCtD
Sorafenib—Angiopathy—Prednisone—multiple sclerosis	0.000156	0.000786	CcSEcCtD
Sorafenib—Immune system disorder—Prednisone—multiple sclerosis	0.000155	0.000783	CcSEcCtD
Sorafenib—Anaphylactic shock—Triamcinolone—multiple sclerosis	0.000155	0.000779	CcSEcCtD
Sorafenib—Anaphylactic shock—Methylprednisolone—multiple sclerosis	0.000154	0.000778	CcSEcCtD
Sorafenib—Syncope—Betamethasone—multiple sclerosis	0.000154	0.000777	CcSEcCtD
Sorafenib—Syncope—Dexamethasone—multiple sclerosis	0.000154	0.000777	CcSEcCtD
Sorafenib—Arrhythmia—Prednisone—multiple sclerosis	0.000154	0.000774	CcSEcCtD
Sorafenib—Infection—Triamcinolone—multiple sclerosis	0.000154	0.000774	CcSEcCtD
Sorafenib—Infection—Methylprednisolone—multiple sclerosis	0.000153	0.000773	CcSEcCtD
Sorafenib—Shock—Triamcinolone—multiple sclerosis	0.000152	0.000767	CcSEcCtD
Sorafenib—Alopecia—Prednisone—multiple sclerosis	0.000152	0.000766	CcSEcCtD
Sorafenib—CYP2B6—brain—multiple sclerosis	0.000152	0.0012	CbGeAlD
Sorafenib—Shock—Methylprednisolone—multiple sclerosis	0.000152	0.000765	CcSEcCtD
Sorafenib—Hepatobiliary disease—Methotrexate—multiple sclerosis	0.000152	0.000763	CcSEcCtD
Sorafenib—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.000151	0.000763	CcSEcCtD
Sorafenib—Loss of consciousness—Dexamethasone—multiple sclerosis	0.000151	0.000762	CcSEcCtD
Sorafenib—Loss of consciousness—Betamethasone—multiple sclerosis	0.000151	0.000762	CcSEcCtD
Sorafenib—Epistaxis—Methotrexate—multiple sclerosis	0.000151	0.000761	CcSEcCtD
Sorafenib—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.000151	0.000761	CcSEcCtD
Sorafenib—Mental disorder—Prednisone—multiple sclerosis	0.000151	0.000759	CcSEcCtD
Sorafenib—Nausea—Azathioprine—multiple sclerosis	0.000151	0.000759	CcSEcCtD
Sorafenib—CYP3A4—nervous system—multiple sclerosis	0.00015	0.00119	CbGeAlD
Sorafenib—Skin disorder—Methylprednisolone—multiple sclerosis	0.00015	0.000755	CcSEcCtD
Sorafenib—Erythema—Prednisone—multiple sclerosis	0.00015	0.000755	CcSEcCtD
Sorafenib—Malnutrition—Prednisone—multiple sclerosis	0.00015	0.000755	CcSEcCtD
Sorafenib—Hypertension—Betamethasone—multiple sclerosis	0.000149	0.000748	CcSEcCtD
Sorafenib—Hypertension—Dexamethasone—multiple sclerosis	0.000149	0.000748	CcSEcCtD
Sorafenib—CYP2D6—nervous system—multiple sclerosis	0.000148	0.00117	CbGeAlD
Sorafenib—Asthenia—Mitoxantrone—multiple sclerosis	0.000147	0.000741	CcSEcCtD
Sorafenib—Myalgia—Dexamethasone—multiple sclerosis	0.000147	0.000738	CcSEcCtD
Sorafenib—Myalgia—Betamethasone—multiple sclerosis	0.000147	0.000738	CcSEcCtD
Sorafenib—Haemoglobin—Methotrexate—multiple sclerosis	0.000145	0.000728	CcSEcCtD
Sorafenib—CYP3A4—central nervous system—multiple sclerosis	0.000145	0.00114	CbGeAlD
Sorafenib—Pain—Prednisolone—multiple sclerosis	0.000144	0.000725	CcSEcCtD
Sorafenib—Haemorrhage—Methotrexate—multiple sclerosis	0.000144	0.000724	CcSEcCtD
Sorafenib—CYP2D6—central nervous system—multiple sclerosis	0.000142	0.00113	CbGeAlD
Sorafenib—Urinary tract disorder—Methotrexate—multiple sclerosis	0.000142	0.000715	CcSEcCtD
Sorafenib—ABCB1—medulla oblongata—multiple sclerosis	0.000141	0.00112	CbGeAlD
Sorafenib—Urethral disorder—Methotrexate—multiple sclerosis	0.000141	0.00071	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	0.000141	0.00071	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	0.000141	0.000708	CcSEcCtD
Sorafenib—Anaphylactic shock—Dexamethasone—multiple sclerosis	0.00014	0.000707	CcSEcCtD
Sorafenib—Anaphylactic shock—Betamethasone—multiple sclerosis	0.00014	0.000707	CcSEcCtD
Sorafenib—Diarrhoea—Mitoxantrone—multiple sclerosis	0.00014	0.000707	CcSEcCtD
Sorafenib—Infection—Dexamethasone—multiple sclerosis	0.00014	0.000703	CcSEcCtD
Sorafenib—Infection—Betamethasone—multiple sclerosis	0.00014	0.000703	CcSEcCtD
Sorafenib—CYP2D6—cerebellum—multiple sclerosis	0.000139	0.0011	CbGeAlD
Sorafenib—Anaemia—Prednisone—multiple sclerosis	0.000139	0.000697	CcSEcCtD
Sorafenib—Shock—Dexamethasone—multiple sclerosis	0.000138	0.000696	CcSEcCtD
Sorafenib—Shock—Betamethasone—multiple sclerosis	0.000138	0.000696	CcSEcCtD
Sorafenib—Dyspnoea—Triamcinolone—multiple sclerosis	0.000138	0.000695	CcSEcCtD
Sorafenib—Nervous system disorder—Dexamethasone—multiple sclerosis	0.000138	0.000693	CcSEcCtD
Sorafenib—Nervous system disorder—Betamethasone—multiple sclerosis	0.000138	0.000693	CcSEcCtD
Sorafenib—Thrombocytopenia—Betamethasone—multiple sclerosis	0.000138	0.000692	CcSEcCtD
Sorafenib—Thrombocytopenia—Dexamethasone—multiple sclerosis	0.000138	0.000692	CcSEcCtD
Sorafenib—Angioedema—Prednisone—multiple sclerosis	0.000137	0.000689	CcSEcCtD
Sorafenib—Dyspepsia—Triamcinolone—multiple sclerosis	0.000136	0.000686	CcSEcCtD
Sorafenib—Erythema multiforme—Methotrexate—multiple sclerosis	0.000136	0.000685	CcSEcCtD
Sorafenib—Dyspepsia—Methylprednisolone—multiple sclerosis	0.000136	0.000684	CcSEcCtD
Sorafenib—Syncope—Prednisone—multiple sclerosis	0.000134	0.000677	CcSEcCtD
Sorafenib—Tinnitus—Methotrexate—multiple sclerosis	0.000134	0.000675	CcSEcCtD
Sorafenib—Anorexia—Betamethasone—multiple sclerosis	0.000134	0.000674	CcSEcCtD
Sorafenib—Anorexia—Dexamethasone—multiple sclerosis	0.000134	0.000674	CcSEcCtD
Sorafenib—Urticaria—Prednisolone—multiple sclerosis	0.000134	0.000673	CcSEcCtD
Sorafenib—Cardiac disorder—Methotrexate—multiple sclerosis	0.000134	0.000672	CcSEcCtD
Sorafenib—Fatigue—Triamcinolone—multiple sclerosis	0.000133	0.000672	CcSEcCtD
Sorafenib—Fatigue—Methylprednisolone—multiple sclerosis	0.000133	0.00067	CcSEcCtD
Sorafenib—Pain—Triamcinolone—multiple sclerosis	0.000132	0.000666	CcSEcCtD
Sorafenib—Loss of consciousness—Prednisone—multiple sclerosis	0.000132	0.000663	CcSEcCtD
Sorafenib—Angiopathy—Methotrexate—multiple sclerosis	0.000131	0.000657	CcSEcCtD
Sorafenib—Vomiting—Mitoxantrone—multiple sclerosis	0.00013	0.000657	CcSEcCtD
Sorafenib—Immune system disorder—Methotrexate—multiple sclerosis	0.00013	0.000654	CcSEcCtD
Sorafenib—Mediastinal disorder—Methotrexate—multiple sclerosis	0.00013	0.000653	CcSEcCtD
Sorafenib—Hypertension—Prednisone—multiple sclerosis	0.000129	0.000651	CcSEcCtD
Sorafenib—Rash—Mitoxantrone—multiple sclerosis	0.000129	0.000651	CcSEcCtD
Sorafenib—ABCB1—midbrain—multiple sclerosis	0.000129	0.00102	CbGeAlD
Sorafenib—Dermatitis—Mitoxantrone—multiple sclerosis	0.000129	0.000651	CcSEcCtD
Sorafenib—Headache—Mitoxantrone—multiple sclerosis	0.000129	0.000647	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	0.000128	0.000644	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	0.000128	0.000644	CcSEcCtD
Sorafenib—Arthralgia—Prednisone—multiple sclerosis	0.000128	0.000642	CcSEcCtD
Sorafenib—Myalgia—Prednisone—multiple sclerosis	0.000128	0.000642	CcSEcCtD
Sorafenib—Alopecia—Methotrexate—multiple sclerosis	0.000127	0.00064	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.000127	0.000638	CcSEcCtD
Sorafenib—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.000126	0.000636	CcSEcCtD
Sorafenib—ABCB1—spinal cord—multiple sclerosis	0.000126	0.000998	CbGeAlD
Sorafenib—Mental disorder—Methotrexate—multiple sclerosis	0.000126	0.000635	CcSEcCtD
Sorafenib—Malnutrition—Methotrexate—multiple sclerosis	0.000125	0.000631	CcSEcCtD
Sorafenib—Erythema—Methotrexate—multiple sclerosis	0.000125	0.000631	CcSEcCtD
Sorafenib—Hypersensitivity—Prednisolone—multiple sclerosis	0.000124	0.000624	CcSEcCtD
Sorafenib—Dyspepsia—Betamethasone—multiple sclerosis	0.000124	0.000622	CcSEcCtD
Sorafenib—Dyspepsia—Dexamethasone—multiple sclerosis	0.000124	0.000622	CcSEcCtD
Sorafenib—Urticaria—Triamcinolone—multiple sclerosis	0.000123	0.000619	CcSEcCtD
Sorafenib—Urticaria—Methylprednisolone—multiple sclerosis	0.000123	0.000618	CcSEcCtD
Sorafenib—Dysgeusia—Methotrexate—multiple sclerosis	0.000123	0.000618	CcSEcCtD
Sorafenib—Body temperature increased—Triamcinolone—multiple sclerosis	0.000122	0.000616	CcSEcCtD
Sorafenib—Anaphylactic shock—Prednisone—multiple sclerosis	0.000122	0.000616	CcSEcCtD
Sorafenib—Abdominal pain—Methylprednisolone—multiple sclerosis	0.000122	0.000615	CcSEcCtD
Sorafenib—Decreased appetite—Betamethasone—multiple sclerosis	0.000122	0.000615	CcSEcCtD
Sorafenib—Decreased appetite—Dexamethasone—multiple sclerosis	0.000122	0.000615	CcSEcCtD
Sorafenib—Nausea—Mitoxantrone—multiple sclerosis	0.000122	0.000614	CcSEcCtD
Sorafenib—Infection—Prednisone—multiple sclerosis	0.000122	0.000612	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.000121	0.00061	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.000121	0.00061	CcSEcCtD
Sorafenib—Fatigue—Dexamethasone—multiple sclerosis	0.000121	0.00061	CcSEcCtD
Sorafenib—Fatigue—Betamethasone—multiple sclerosis	0.000121	0.00061	CcSEcCtD
Sorafenib—Shock—Prednisone—multiple sclerosis	0.00012	0.000606	CcSEcCtD
Sorafenib—Pain—Dexamethasone—multiple sclerosis	0.00012	0.000605	CcSEcCtD
Sorafenib—Pain—Betamethasone—multiple sclerosis	0.00012	0.000605	CcSEcCtD
Sorafenib—Nervous system disorder—Prednisone—multiple sclerosis	0.00012	0.000604	CcSEcCtD
Sorafenib—Skin disorder—Prednisone—multiple sclerosis	0.000119	0.000598	CcSEcCtD
Sorafenib—Anorexia—Prednisone—multiple sclerosis	0.000117	0.000587	CcSEcCtD
Sorafenib—Anaemia—Methotrexate—multiple sclerosis	0.000116	0.000583	CcSEcCtD
Sorafenib—Gastrointestinal pain—Betamethasone—multiple sclerosis	0.000115	0.000578	CcSEcCtD
Sorafenib—Gastrointestinal pain—Dexamethasone—multiple sclerosis	0.000115	0.000578	CcSEcCtD
Sorafenib—Hypersensitivity—Triamcinolone—multiple sclerosis	0.000114	0.000574	CcSEcCtD
Sorafenib—Hypersensitivity—Methylprednisolone—multiple sclerosis	0.000114	0.000573	CcSEcCtD
Sorafenib—CYP2D6—brain—multiple sclerosis	0.000113	0.000894	CbGeAlD
Sorafenib—Leukopenia—Methotrexate—multiple sclerosis	0.000112	0.000564	CcSEcCtD
Sorafenib—Urticaria—Dexamethasone—multiple sclerosis	0.000112	0.000562	CcSEcCtD
Sorafenib—Urticaria—Betamethasone—multiple sclerosis	0.000112	0.000562	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Prednisone—multiple sclerosis	0.000111	0.000561	CcSEcCtD
Sorafenib—Dizziness—Prednisolone—multiple sclerosis	0.000111	0.00056	CcSEcCtD
Sorafenib—Asthenia—Triamcinolone—multiple sclerosis	0.000111	0.000559	CcSEcCtD
Sorafenib—Body temperature increased—Betamethasone—multiple sclerosis	0.000111	0.000559	CcSEcCtD
Sorafenib—Abdominal pain—Dexamethasone—multiple sclerosis	0.000111	0.000559	CcSEcCtD
Sorafenib—Body temperature increased—Dexamethasone—multiple sclerosis	0.000111	0.000559	CcSEcCtD
Sorafenib—Abdominal pain—Betamethasone—multiple sclerosis	0.000111	0.000559	CcSEcCtD
Sorafenib—Asthenia—Methylprednisolone—multiple sclerosis	0.000111	0.000558	CcSEcCtD
Sorafenib—Pruritus—Triamcinolone—multiple sclerosis	0.00011	0.000551	CcSEcCtD
Sorafenib—Cough—Methotrexate—multiple sclerosis	0.000109	0.00055	CcSEcCtD
Sorafenib—Pruritus—Methylprednisolone—multiple sclerosis	0.000109	0.00055	CcSEcCtD
Sorafenib—Dyspepsia—Prednisone—multiple sclerosis	0.000108	0.000542	CcSEcCtD
Sorafenib—Arthralgia—Methotrexate—multiple sclerosis	0.000107	0.000537	CcSEcCtD
Sorafenib—Myalgia—Methotrexate—multiple sclerosis	0.000107	0.000537	CcSEcCtD
Sorafenib—Decreased appetite—Prednisone—multiple sclerosis	0.000106	0.000535	CcSEcCtD
Sorafenib—ABCB1—nervous system—multiple sclerosis	0.000106	0.000841	CbGeAlD
Sorafenib—Rash—Prednisolone—multiple sclerosis	0.000106	0.000534	CcSEcCtD
Sorafenib—Dermatitis—Prednisolone—multiple sclerosis	0.000106	0.000534	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	0.000106	0.000533	CcSEcCtD
Sorafenib—Diarrhoea—Methylprednisolone—multiple sclerosis	0.000106	0.000532	CcSEcCtD
Sorafenib—Fatigue—Prednisone—multiple sclerosis	0.000105	0.000531	CcSEcCtD
Sorafenib—Headache—Prednisolone—multiple sclerosis	0.000105	0.000531	CcSEcCtD
Sorafenib—Constipation—Prednisone—multiple sclerosis	0.000105	0.000527	CcSEcCtD
Sorafenib—Dizziness—Triamcinolone—multiple sclerosis	0.000102	0.000515	CcSEcCtD
Sorafenib—ABCB1—central nervous system—multiple sclerosis	0.000102	0.00081	CbGeAlD
Sorafenib—Anaphylactic shock—Methotrexate—multiple sclerosis	0.000102	0.000515	CcSEcCtD
Sorafenib—Dizziness—Methylprednisolone—multiple sclerosis	0.000102	0.000514	CcSEcCtD
Sorafenib—Infection—Methotrexate—multiple sclerosis	0.000102	0.000511	CcSEcCtD
Sorafenib—Asthenia—Dexamethasone—multiple sclerosis	0.000101	0.000507	CcSEcCtD
Sorafenib—Asthenia—Betamethasone—multiple sclerosis	0.000101	0.000507	CcSEcCtD
Sorafenib—Nervous system disorder—Methotrexate—multiple sclerosis	0.0001	0.000505	CcSEcCtD
Sorafenib—Thrombocytopenia—Methotrexate—multiple sclerosis	0.0001	0.000504	CcSEcCtD
Sorafenib—Gastrointestinal pain—Prednisone—multiple sclerosis	0.0001	0.000504	CcSEcCtD
Sorafenib—ABCB1—cerebellum—multiple sclerosis	0.0001	0.000792	CbGeAlD
Sorafenib—Nausea—Prednisolone—multiple sclerosis	0.0001	0.000503	CcSEcCtD
Sorafenib—Pruritus—Dexamethasone—multiple sclerosis	9.94e-05	0.0005	CcSEcCtD
Sorafenib—Pruritus—Betamethasone—multiple sclerosis	9.94e-05	0.0005	CcSEcCtD
Sorafenib—Skin disorder—Methotrexate—multiple sclerosis	9.93e-05	0.0005	CcSEcCtD
Sorafenib—Vomiting—Triamcinolone—multiple sclerosis	9.84e-05	0.000496	CcSEcCtD
Sorafenib—Vomiting—Methylprednisolone—multiple sclerosis	9.82e-05	0.000494	CcSEcCtD
Sorafenib—Rash—Triamcinolone—multiple sclerosis	9.76e-05	0.000491	CcSEcCtD
Sorafenib—Dermatitis—Triamcinolone—multiple sclerosis	9.75e-05	0.000491	CcSEcCtD
Sorafenib—Anorexia—Methotrexate—multiple sclerosis	9.74e-05	0.000491	CcSEcCtD
Sorafenib—Rash—Methylprednisolone—multiple sclerosis	9.74e-05	0.00049	CcSEcCtD
Sorafenib—Dermatitis—Methylprednisolone—multiple sclerosis	9.73e-05	0.00049	CcSEcCtD
Sorafenib—Urticaria—Prednisone—multiple sclerosis	9.72e-05	0.000489	CcSEcCtD
Sorafenib—Headache—Triamcinolone—multiple sclerosis	9.7e-05	0.000488	CcSEcCtD
Sorafenib—Headache—Methylprednisolone—multiple sclerosis	9.67e-05	0.000487	CcSEcCtD
Sorafenib—Body temperature increased—Prednisone—multiple sclerosis	9.67e-05	0.000487	CcSEcCtD
Sorafenib—Abdominal pain—Prednisone—multiple sclerosis	9.67e-05	0.000487	CcSEcCtD
Sorafenib—Diarrhoea—Betamethasone—multiple sclerosis	9.61e-05	0.000484	CcSEcCtD
Sorafenib—Diarrhoea—Dexamethasone—multiple sclerosis	9.61e-05	0.000484	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	9.31e-05	0.000469	CcSEcCtD
Sorafenib—Dizziness—Dexamethasone—multiple sclerosis	9.29e-05	0.000468	CcSEcCtD
Sorafenib—Dizziness—Betamethasone—multiple sclerosis	9.29e-05	0.000468	CcSEcCtD
Sorafenib—Nausea—Triamcinolone—multiple sclerosis	9.19e-05	0.000463	CcSEcCtD
Sorafenib—Nausea—Methylprednisolone—multiple sclerosis	9.17e-05	0.000462	CcSEcCtD
Sorafenib—Dyspnoea—Methotrexate—multiple sclerosis	9.11e-05	0.000459	CcSEcCtD
Sorafenib—Hypersensitivity—Prednisone—multiple sclerosis	9.01e-05	0.000454	CcSEcCtD
Sorafenib—Dyspepsia—Methotrexate—multiple sclerosis	9e-05	0.000453	CcSEcCtD
Sorafenib—Vomiting—Betamethasone—multiple sclerosis	8.93e-05	0.00045	CcSEcCtD
Sorafenib—Vomiting—Dexamethasone—multiple sclerosis	8.93e-05	0.00045	CcSEcCtD
Sorafenib—Decreased appetite—Methotrexate—multiple sclerosis	8.89e-05	0.000447	CcSEcCtD
Sorafenib—Rash—Betamethasone—multiple sclerosis	8.86e-05	0.000446	CcSEcCtD
Sorafenib—Rash—Dexamethasone—multiple sclerosis	8.86e-05	0.000446	CcSEcCtD
Sorafenib—Dermatitis—Dexamethasone—multiple sclerosis	8.85e-05	0.000445	CcSEcCtD
Sorafenib—Dermatitis—Betamethasone—multiple sclerosis	8.85e-05	0.000445	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Methotrexate—multiple sclerosis	8.82e-05	0.000444	CcSEcCtD
Sorafenib—Fatigue—Methotrexate—multiple sclerosis	8.81e-05	0.000444	CcSEcCtD
Sorafenib—Headache—Dexamethasone—multiple sclerosis	8.8e-05	0.000443	CcSEcCtD
Sorafenib—Headache—Betamethasone—multiple sclerosis	8.8e-05	0.000443	CcSEcCtD
Sorafenib—Asthenia—Prednisone—multiple sclerosis	8.78e-05	0.000442	CcSEcCtD
Sorafenib—Pain—Methotrexate—multiple sclerosis	8.74e-05	0.00044	CcSEcCtD
Sorafenib—Pruritus—Prednisone—multiple sclerosis	8.65e-05	0.000436	CcSEcCtD
Sorafenib—Diarrhoea—Prednisone—multiple sclerosis	8.37e-05	0.000421	CcSEcCtD
Sorafenib—Gastrointestinal pain—Methotrexate—multiple sclerosis	8.36e-05	0.000421	CcSEcCtD
Sorafenib—Nausea—Betamethasone—multiple sclerosis	8.34e-05	0.00042	CcSEcCtD
Sorafenib—Nausea—Dexamethasone—multiple sclerosis	8.34e-05	0.00042	CcSEcCtD
Sorafenib—ABCB1—brain—multiple sclerosis	8.12e-05	0.000643	CbGeAlD
Sorafenib—Urticaria—Methotrexate—multiple sclerosis	8.12e-05	0.000409	CcSEcCtD
Sorafenib—Dizziness—Prednisone—multiple sclerosis	8.09e-05	0.000407	CcSEcCtD
Sorafenib—Abdominal pain—Methotrexate—multiple sclerosis	8.08e-05	0.000407	CcSEcCtD
Sorafenib—Body temperature increased—Methotrexate—multiple sclerosis	8.08e-05	0.000407	CcSEcCtD
Sorafenib—Vomiting—Prednisone—multiple sclerosis	7.78e-05	0.000392	CcSEcCtD
Sorafenib—Rash—Prednisone—multiple sclerosis	7.71e-05	0.000388	CcSEcCtD
Sorafenib—Dermatitis—Prednisone—multiple sclerosis	7.7e-05	0.000388	CcSEcCtD
Sorafenib—Headache—Prednisone—multiple sclerosis	7.66e-05	0.000386	CcSEcCtD
Sorafenib—Hypersensitivity—Methotrexate—multiple sclerosis	7.53e-05	0.000379	CcSEcCtD
Sorafenib—Asthenia—Methotrexate—multiple sclerosis	7.33e-05	0.000369	CcSEcCtD
Sorafenib—Nausea—Prednisone—multiple sclerosis	7.26e-05	0.000366	CcSEcCtD
Sorafenib—Pruritus—Methotrexate—multiple sclerosis	7.23e-05	0.000364	CcSEcCtD
Sorafenib—Diarrhoea—Methotrexate—multiple sclerosis	6.99e-05	0.000352	CcSEcCtD
Sorafenib—Dizziness—Methotrexate—multiple sclerosis	6.76e-05	0.00034	CcSEcCtD
Sorafenib—Vomiting—Methotrexate—multiple sclerosis	6.5e-05	0.000327	CcSEcCtD
Sorafenib—Rash—Methotrexate—multiple sclerosis	6.44e-05	0.000325	CcSEcCtD
Sorafenib—Dermatitis—Methotrexate—multiple sclerosis	6.44e-05	0.000324	CcSEcCtD
Sorafenib—Headache—Methotrexate—multiple sclerosis	6.4e-05	0.000322	CcSEcCtD
Sorafenib—Nausea—Methotrexate—multiple sclerosis	6.07e-05	0.000306	CcSEcCtD
Sorafenib—Vismodegib—ALB—multiple sclerosis	4.38e-05	1	CrCbGaD
Sorafenib—HTR2C—Signaling by GPCR—TYK2—multiple sclerosis	5.62e-06	2.52e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	5.62e-06	2.52e-05	CbGpPWpGaD
Sorafenib—MAPK11—Gene Expression—MYC—multiple sclerosis	5.62e-06	2.52e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—TYK2—multiple sclerosis	5.62e-06	2.52e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Innate Immune System—IL6—multiple sclerosis	5.61e-06	2.51e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—IL1B—multiple sclerosis	5.58e-06	2.5e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—CD4—multiple sclerosis	5.58e-06	2.5e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—CCL2—multiple sclerosis	5.58e-06	2.5e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—CCL2—multiple sclerosis	5.58e-06	2.5e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—IL2—multiple sclerosis	5.58e-06	2.5e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—IFNG—multiple sclerosis	5.57e-06	2.5e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—TYK2—multiple sclerosis	5.56e-06	2.49e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—STAT3—multiple sclerosis	5.56e-06	2.49e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—IL2—multiple sclerosis	5.56e-06	2.49e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CCR5—multiple sclerosis	5.54e-06	2.48e-05	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—MAPK1—multiple sclerosis	5.53e-06	2.48e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—TYK2—multiple sclerosis	5.5e-06	2.46e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—STAT3—multiple sclerosis	5.48e-06	2.46e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—STAT3—multiple sclerosis	5.48e-06	2.46e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—IL2RA—multiple sclerosis	5.46e-06	2.45e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—IL2—multiple sclerosis	5.43e-06	2.43e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—BCHE—multiple sclerosis	5.43e-06	2.43e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—IL2—multiple sclerosis	5.42e-06	2.43e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—POMC—multiple sclerosis	5.41e-06	2.42e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—APOE—multiple sclerosis	5.4e-06	2.42e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—POMC—multiple sclerosis	5.39e-06	2.42e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CD86—multiple sclerosis	5.39e-06	2.42e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—CD4—multiple sclerosis	5.38e-06	2.41e-05	CbGpPWpGaD
Sorafenib—CDK7—Disease—IL6—multiple sclerosis	5.36e-06	2.4e-05	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—IL6—multiple sclerosis	5.33e-06	2.39e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—POMC—multiple sclerosis	5.33e-06	2.39e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—POMC—multiple sclerosis	5.33e-06	2.39e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CCL5—multiple sclerosis	5.31e-06	2.38e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—CCL2—multiple sclerosis	5.29e-06	2.37e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—CCL2—multiple sclerosis	5.28e-06	2.36e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—MMP9—multiple sclerosis	5.28e-06	2.36e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—APOE—multiple sclerosis	5.26e-06	2.36e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—APOE—multiple sclerosis	5.21e-06	2.34e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—STAT3—multiple sclerosis	5.2e-06	2.33e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—STAT3—multiple sclerosis	5.19e-06	2.32e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—MYC—multiple sclerosis	5.17e-06	2.31e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—TGFB1—multiple sclerosis	5.16e-06	2.31e-05	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—IL2—multiple sclerosis	5.15e-06	2.31e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—MMP9—multiple sclerosis	5.14e-06	2.3e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	5.12e-06	2.3e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	5.12e-06	2.3e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CD80—multiple sclerosis	5.11e-06	2.29e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	5.1e-06	2.28e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—RRM1—multiple sclerosis	5.07e-06	2.27e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—TYK2—multiple sclerosis	5.06e-06	2.27e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—TYK2—multiple sclerosis	5.06e-06	2.27e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—STAT3—multiple sclerosis	5.06e-06	2.27e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—MAPK1—multiple sclerosis	5.06e-06	2.26e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—APOE—multiple sclerosis	5.04e-06	2.26e-05	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—IL6—multiple sclerosis	5e-06	2.24e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—MAPK1—multiple sclerosis	4.98e-06	2.23e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—MAPK1—multiple sclerosis	4.98e-06	2.23e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—IL1B—multiple sclerosis	4.97e-06	2.23e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—CD4—multiple sclerosis	4.97e-06	2.23e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—IL2—multiple sclerosis	4.95e-06	2.22e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—SPP1—multiple sclerosis	4.92e-06	2.2e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CD80—multiple sclerosis	4.88e-06	2.18e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—POMC—multiple sclerosis	4.86e-06	2.18e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—ALB—multiple sclerosis	4.86e-06	2.17e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—ALB—multiple sclerosis	4.86e-06	2.17e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—BCHE—multiple sclerosis	4.84e-06	2.17e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—TYK2—multiple sclerosis	4.81e-06	2.15e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—STAT3—multiple sclerosis	4.8e-06	2.15e-05	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—IL6—multiple sclerosis	4.8e-06	2.15e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—TYK2—multiple sclerosis	4.79e-06	2.15e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—STAT3—multiple sclerosis	4.79e-06	2.15e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CCR5—multiple sclerosis	4.78e-06	2.14e-05	CbGpPWpGaD
Sorafenib—ABCB1—Transmembrane transport of small molecules—ALB—multiple sclerosis	4.76e-06	2.13e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CCL2—multiple sclerosis	4.76e-06	2.13e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—MAPK1—multiple sclerosis	4.73e-06	2.12e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—BCHE—multiple sclerosis	4.73e-06	2.12e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—MAPK1—multiple sclerosis	4.72e-06	2.11e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IL2RA—multiple sclerosis	4.72e-06	2.11e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—MYC—multiple sclerosis	4.7e-06	2.11e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—TGFB1—multiple sclerosis	4.69e-06	2.1e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—STAT3—multiple sclerosis	4.69e-06	2.1e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—IL2—multiple sclerosis	4.68e-06	2.1e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—STAT3—multiple sclerosis	4.68e-06	2.09e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—IL2—multiple sclerosis	4.67e-06	2.09e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	4.67e-06	2.09e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—POMC—multiple sclerosis	4.63e-06	2.08e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—IL2—multiple sclerosis	4.63e-06	2.07e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—MAPK1—multiple sclerosis	4.6e-06	2.06e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—STAT3—multiple sclerosis	4.57e-06	2.05e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CD80—multiple sclerosis	4.56e-06	2.04e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CCL2—multiple sclerosis	4.53e-06	2.03e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—POMC—multiple sclerosis	4.52e-06	2.02e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—POMC—multiple sclerosis	4.48e-06	2.01e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—MYC—multiple sclerosis	4.46e-06	2e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—BCHE—multiple sclerosis	4.45e-06	2e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—TGFB1—multiple sclerosis	4.45e-06	1.99e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—MYC—multiple sclerosis	4.45e-06	1.99e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—TGFB1—multiple sclerosis	4.44e-06	1.99e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—MAPK1—multiple sclerosis	4.44e-06	1.99e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—MMP9—multiple sclerosis	4.42e-06	1.98e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—BCHE—multiple sclerosis	4.42e-06	1.98e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—MMP9—multiple sclerosis	4.38e-06	1.96e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	4.38e-06	1.96e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—MAPK1—multiple sclerosis	4.37e-06	1.96e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—MYC—multiple sclerosis	4.36e-06	1.95e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—MAPK1—multiple sclerosis	4.36e-06	1.95e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—APOE—multiple sclerosis	4.35e-06	1.95e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—TGFB1—multiple sclerosis	4.35e-06	1.95e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—POMC—multiple sclerosis	4.33e-06	1.94e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—TYK2—multiple sclerosis	4.32e-06	1.93e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—STAT3—multiple sclerosis	4.32e-06	1.93e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—MAPK1—multiple sclerosis	4.27e-06	1.91e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—MAPK1—multiple sclerosis	4.25e-06	1.9e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—MYC—multiple sclerosis	4.25e-06	1.9e-05	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—IL6—multiple sclerosis	4.25e-06	1.9e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CCL2—multiple sclerosis	4.24e-06	1.9e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—TGFB1—multiple sclerosis	4.24e-06	1.9e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—IL2—multiple sclerosis	4.21e-06	1.89e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—IL2—multiple sclerosis	4.21e-06	1.89e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—STAT3—multiple sclerosis	4.17e-06	1.87e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—MAPK1—multiple sclerosis	4.16e-06	1.86e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—MAPK1—multiple sclerosis	4.15e-06	1.86e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—ALB—multiple sclerosis	4.12e-06	1.85e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—TYK2—multiple sclerosis	4.12e-06	1.84e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—ALB—multiple sclerosis	4.08e-06	1.83e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—MYC—multiple sclerosis	4.01e-06	1.8e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—TGFB1—multiple sclerosis	4e-06	1.79e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—IL2—multiple sclerosis	4e-06	1.79e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	3.99e-06	1.79e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—IL2—multiple sclerosis	3.99e-06	1.79e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—MMP9—multiple sclerosis	3.99e-06	1.79e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—MMP9—multiple sclerosis	3.99e-06	1.79e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CD80—multiple sclerosis	3.94e-06	1.76e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—STAT3—multiple sclerosis	3.93e-06	1.76e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—MAPK1—multiple sclerosis	3.92e-06	1.76e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—STAT3—multiple sclerosis	3.89e-06	1.74e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—IL6—multiple sclerosis	3.89e-06	1.74e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—APOE—multiple sclerosis	3.86e-06	1.73e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—TYK2—multiple sclerosis	3.85e-06	1.72e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—STAT3—multiple sclerosis	3.85e-06	1.72e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—IL6—multiple sclerosis	3.83e-06	1.72e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—IL6—multiple sclerosis	3.83e-06	1.72e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—MAPK1—multiple sclerosis	3.79e-06	1.7e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—MMP9—multiple sclerosis	3.78e-06	1.7e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—MMP9—multiple sclerosis	3.77e-06	1.69e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—BCHE—multiple sclerosis	3.77e-06	1.69e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—APOE—multiple sclerosis	3.77e-06	1.69e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—POMC—multiple sclerosis	3.74e-06	1.67e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CCL2—multiple sclerosis	3.66e-06	1.64e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—MYC—multiple sclerosis	3.65e-06	1.64e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—TGFB1—multiple sclerosis	3.64e-06	1.63e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—IL6—multiple sclerosis	3.63e-06	1.63e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—IL6—multiple sclerosis	3.63e-06	1.62e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—MYC—multiple sclerosis	3.62e-06	1.62e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—TGFB1—multiple sclerosis	3.61e-06	1.62e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—IL2—multiple sclerosis	3.59e-06	1.61e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—MAPK1—multiple sclerosis	3.58e-06	1.6e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—MYC—multiple sclerosis	3.58e-06	1.6e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—MAPK1—multiple sclerosis	3.57e-06	1.6e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—TGFB1—multiple sclerosis	3.57e-06	1.6e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—STAT3—multiple sclerosis	3.55e-06	1.59e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—STAT3—multiple sclerosis	3.55e-06	1.59e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—MAPK1—multiple sclerosis	3.54e-06	1.59e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—IL6—multiple sclerosis	3.54e-06	1.58e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—MAPK1—multiple sclerosis	3.5e-06	1.57e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—IL2—multiple sclerosis	3.43e-06	1.53e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—IL6—multiple sclerosis	3.41e-06	1.53e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—MMP9—multiple sclerosis	3.4e-06	1.52e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—STAT3—multiple sclerosis	3.36e-06	1.51e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—IL6—multiple sclerosis	3.36e-06	1.5e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—STAT3—multiple sclerosis	3.36e-06	1.5e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—IL6—multiple sclerosis	3.35e-06	1.5e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TYK2—multiple sclerosis	3.32e-06	1.49e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—POMC—multiple sclerosis	3.31e-06	1.48e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—MYC—multiple sclerosis	3.29e-06	1.48e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—MYC—multiple sclerosis	3.29e-06	1.48e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—TGFB1—multiple sclerosis	3.29e-06	1.47e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—TGFB1—multiple sclerosis	3.29e-06	1.47e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—IL6—multiple sclerosis	3.28e-06	1.47e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—IL6—multiple sclerosis	3.27e-06	1.46e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—APOE—multiple sclerosis	3.26e-06	1.46e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—MMP9—multiple sclerosis	3.24e-06	1.45e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—POMC—multiple sclerosis	3.24e-06	1.45e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—MAPK1—multiple sclerosis	3.22e-06	1.44e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—MAPK1—multiple sclerosis	3.22e-06	1.44e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—IL2—multiple sclerosis	3.2e-06	1.43e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—IL6—multiple sclerosis	3.19e-06	1.43e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—IL6—multiple sclerosis	3.19e-06	1.43e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—MYC—multiple sclerosis	3.13e-06	1.4e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—TGFB1—multiple sclerosis	3.12e-06	1.4e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—MYC—multiple sclerosis	3.12e-06	1.4e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—TGFB1—multiple sclerosis	3.11e-06	1.39e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—MAPK1—multiple sclerosis	3.06e-06	1.37e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—MAPK1—multiple sclerosis	3.05e-06	1.37e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MMP9—multiple sclerosis	3.03e-06	1.36e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—STAT3—multiple sclerosis	3.02e-06	1.35e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—ALB—multiple sclerosis	3.02e-06	1.35e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—IL6—multiple sclerosis	3.02e-06	1.35e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—ALB—multiple sclerosis	2.95e-06	1.32e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—APOE—multiple sclerosis	2.91e-06	1.31e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—BCHE—multiple sclerosis	2.91e-06	1.3e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—IL6—multiple sclerosis	2.91e-06	1.3e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—STAT3—multiple sclerosis	2.88e-06	1.29e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—APOE—multiple sclerosis	2.84e-06	1.27e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—MYC—multiple sclerosis	2.81e-06	1.26e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—POMC—multiple sclerosis	2.8e-06	1.26e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—TGFB1—multiple sclerosis	2.8e-06	1.26e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IL2—multiple sclerosis	2.76e-06	1.24e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—IL6—multiple sclerosis	2.75e-06	1.23e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—MAPK1—multiple sclerosis	2.75e-06	1.23e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—IL6—multiple sclerosis	2.75e-06	1.23e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—IL6—multiple sclerosis	2.72e-06	1.22e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—STAT3—multiple sclerosis	2.69e-06	1.21e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—IL6—multiple sclerosis	2.69e-06	1.2e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—APOE—multiple sclerosis	2.68e-06	1.2e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—MYC—multiple sclerosis	2.68e-06	1.2e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—TGFB1—multiple sclerosis	2.67e-06	1.2e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—APOE—multiple sclerosis	2.66e-06	1.19e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—MAPK1—multiple sclerosis	2.62e-06	1.17e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MMP9—multiple sclerosis	2.62e-06	1.17e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—ALB—multiple sclerosis	2.56e-06	1.15e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MYC—multiple sclerosis	2.5e-06	1.12e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—POMC—multiple sclerosis	2.5e-06	1.12e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—TGFB1—multiple sclerosis	2.5e-06	1.12e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—IL6—multiple sclerosis	2.48e-06	1.11e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—IL6—multiple sclerosis	2.48e-06	1.11e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MAPK1—multiple sclerosis	2.45e-06	1.1e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—POMC—multiple sclerosis	2.44e-06	1.09e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—IL6—multiple sclerosis	2.35e-06	1.05e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—IL6—multiple sclerosis	2.34e-06	1.05e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—STAT3—multiple sclerosis	2.33e-06	1.04e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—POMC—multiple sclerosis	2.3e-06	1.03e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—POMC—multiple sclerosis	2.28e-06	1.02e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—ALB—multiple sclerosis	2.28e-06	1.02e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—APOE—multiple sclerosis	2.27e-06	1.02e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—ALB—multiple sclerosis	2.23e-06	9.98e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MYC—multiple sclerosis	2.16e-06	9.68e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TGFB1—multiple sclerosis	2.16e-06	9.66e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MAPK1—multiple sclerosis	2.11e-06	9.47e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—IL6—multiple sclerosis	2.11e-06	9.46e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—ALB—multiple sclerosis	2.1e-06	9.4e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—ALB—multiple sclerosis	2.08e-06	9.32e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—IL6—multiple sclerosis	2.01e-06	9.02e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—POMC—multiple sclerosis	1.95e-06	8.74e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—IL6—multiple sclerosis	1.88e-06	8.43e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—ALB—multiple sclerosis	1.78e-06	7.96e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—APOE—multiple sclerosis	1.75e-06	7.85e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IL6—multiple sclerosis	1.62e-06	7.28e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—POMC—multiple sclerosis	1.51e-06	6.74e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ALB—multiple sclerosis	1.37e-06	6.15e-06	CbGpPWpGaD
